Abstract 96P
Background
Determination of MMR functioning in EC is recommended by international guidelines. Its deficiency leads to MSI with intermediate prognosis. Available data have shown a reasonable concordance between IHC-MMR and NGS-MSI. We aim at evaluating the sensitivity and specificity of NGS-MSI obtained from a comprehensive cancer genome profiling (CGP) assay compared with the gold standard IHC-MMR.
Methods
Selected EC patients were profiled using TruSight Oncology500 High Throughput solution. MSI status was determined by 130 noncoding homopolymer regions and at least 40 sites were assessed to provide a score (threshold MSI high>20). IHC-MMR evaluation was collected from standard pathology report.
Results
From March 2022 to May 2023, 404 EC were enrolled. NGS-MSI evaluation was available for 354 (87%; see table). Cohort characteristics are reported in the table. Sensitivity and specificity of NGS-MSI testing compared to IHC-MMR were 99% (n=223/224) and 52% (n= 68/130) respectively, with a concordance rate of 82% (Cohen Kappa = 0.58; p < .0001). The positive predictive value of NGS-MSI was 78% (n=223/285), while the negative predictive value was 99% (n= 68/69). Among the 62 misclassified cases, 19 were MSH6 + MSH2 deficient, 42 MLH1 + PMS2 deficient and 1 was deficient for PMS2, MLH1 and MSH6. 38 MLH1 + PMS2 deficient patients were addressed to MLH1 promoter methylation analysis: results are available for 15 cases (11 hypermethylated, 2 partially hypermethylated). All 19 MSH6 + MSH2 deficient were addressed to genetic counselling: results are available only for 3 patient (1 displaying a MSH2 pathogenic variant). Table: 96P
Characteristics | Cohort (N = 354) | ||
Histotype, n (%) | |||
Endometrioid | 307 (87%) | ||
Serous carcinoma | 18 (5%) | ||
Others | 29 (8%) | ||
FIGO Stage 2019*, n (%) | |||
I-II | 149 (93%) | ||
III-IV | 25 (7%) | ||
MSI status, n (%) | |||
MSI | 69 (19%) | ||
MSS | 285 (81%) | ||
MMR IHC status, n (%) | |||
pMMR | 224 (63%) | ||
dMMR | 130 (37%) |
Conclusions
A moderate concordance between IHC-MMR and NGS-MSI was reported in our study. However, given the approval of immunotherapy in several settings it is important to further characterize the misclassified cases.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Nero: Non-Financial Interests, Personal, Other: Illumina. D. Lorusso: Financial Interests, Personal, Invited Speaker: Clovis, GSK, MSD, AZ, PharmaMar.G. Scambia: Financial Interests, Personal, Invited Speaker: MSD, Clovis, Tesaro, J&J. All other authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract